FDA approves first gene therapy for Duchenne muscular dystrophy 

The Food and Drug Administration June 22 approved the first gene therapy to treat patients aged 4-5 with a confirmed mutation in the Duchenne muscular dystrophy gene. As part of the drug’s accelerated approval, the drugmaker must conduct additional clinical trials to verify the predicted clinical benefit.